209 related articles for article (PubMed ID: 21862953)
21. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
Subramanian ML; Abedi G; Ness S; Ahmed E; Fenberg M; Daly MK; Houranieh A; Feinberg EB
Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
[TBL] [Abstract][Full Text] [Related]
23. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
26. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema.
Acharya NR; Sittivarakul W; Qian Y; Hong KC; Lee SM
Retina; 2011 Oct; 31(9):1871-6. PubMed ID: 21716165
[TBL] [Abstract][Full Text] [Related]
27. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration.
Bhatnagar P; Spaide RF; Takahashi BS; Peragallo JH; Freund KB; Klancnik JM; Cooney MJ; Slakter JS; Sorenson JA; Yannuzzi LA
Retina; 2007 Sep; 27(7):846-50. PubMed ID: 17891007
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
29. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Heier JS; Antoszyk AN; Pavan PR; Leff SR; Rosenfeld PJ; Ciulla TA; Dreyer RF; Gentile RC; Sy JP; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):633.e1-4. PubMed ID: 16483659
[TBL] [Abstract][Full Text] [Related]
30. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema.
Radwan AE; Arcinue CA; Yang P; Artornsombudh P; Abu Al-Fadl EM; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1801-6. PubMed ID: 23519884
[TBL] [Abstract][Full Text] [Related]
31. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
32. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
Dugel PU; Bebchuk JD; Nau J; Reichel E; Singer M; Barak A; Binder S; Jackson TL;
Ophthalmology; 2013 Feb; 120(2):317-27. PubMed ID: 23174399
[TBL] [Abstract][Full Text] [Related]
33. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
34. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
35. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.
Querques G; Azrya S; Martinelli D; Berboucha E; Feldman A; Pece A; Coscas G; Soubrane G; Souied EH
Br J Ophthalmol; 2010 Mar; 94(3):292-6. PubMed ID: 19951942
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients.
De Bats F; Grange JD; Cornut PL; Feldman A; Burillon C; Denis P; Kodjikian L
J Fr Ophtalmol; 2012 Nov; 35(9):661-6. PubMed ID: 23040443
[TBL] [Abstract][Full Text] [Related]
37. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration.
Chang MA; Do DV; Bressler SB; Cassard SD; Gower EW; Bressler NM
Retina; 2010 Sep; 30(8):1171-6. PubMed ID: 20827138
[TBL] [Abstract][Full Text] [Related]
38. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
[TBL] [Abstract][Full Text] [Related]
39. Combination of bevacizumab and bromfenac therapy in age-related macular degeneration: a pilot study.
Wyględowska-Promieńska D; Piotrowska-Gwóźdź A; Piotrowska-Seweryn A; Mazur-Piotrowska G; Rokicki W
Med Sci Monit; 2014 Jul; 20():1168-75. PubMed ID: 25006692
[TBL] [Abstract][Full Text] [Related]
40. TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY.
Semeraro F; Russo A; Delcassi L; Romano MR; Rinaldi M; Chiosi F; Costagliola C
Retina; 2015 Aug; 35(8):1547-54. PubMed ID: 25784358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]